GlassScriptPhysician profile
David A Shore
NPI 1619065067
$82,731.10
in general payments reported to CMS, 2019-2025
66 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,418 · 2020: $1,500 · 2021: $11K · 2022: $17K · 2023: $17K · 2024: $15K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Food and Beverage: $12K · Consulting Fee: $7,900 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,205 · Travel and Lodging: $2,000 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,068.00 |
| Food and Beverage | $12,153.29 |
| Consulting Fee | $7,900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,205.00 |
| Travel and Lodging | $2,000.13 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43,130.16 | 2020-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $17,929.70 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Ascensia Diabetes Care US INC. | $3,511.16 | 2023-2024 | |
| Corcept Therapeutics | $3,068.73 | 2019-2025 | Korlym |
| Novo Nordisk INC | $2,864.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,611.48 | 2019-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $1,269.60 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $1,248.85 | 2019-2025 | |
| Insulet Corporation | $749.27 | 2019-2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $659.05 | 2019-2023 | Farxiga |
| Medtronic, INC. | $582.56 | 2021-2023 | Minimed 780g |
| Ibsa Pharma INC. | $542.79 | 2019-2022 | |
| Lilly USA, LLC | $541.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Horizon Therapeutics Plc | $515.59 | 2020-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $401.86 | 2020-2025 | Gvoke Hypopen, Recorlev |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.